ModifiedColorado Rocky Mountain Health PlansPolicy CS169.Q

Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea

Defines medical necessity and coverage criteria for multiplex nucleic acid (PCR) gastrointestinal pathogen panels used to evaluate infectious diarrhea for Colorado Rocky Mountain Health Plans' commercial members (Community Plan).

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyGastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea

Policy CodePolicy CS169.Q

Change TypeRevised clinical evidence and referencestemplate language removed

Effective DateFeb 1, 2026

Next Review Date

Key ActionOrder multiplex PCR panels targeted to guideline-based indications (eg, fever, bloody stools, persistent or severe diarrhea) and confirm culture when antimicrobial susceptibility or public health subtyping is required.

SourceLink

POLICY UPDATE CHANGES

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.

Removed content/language pertaining to the state of Louisiana.

3-5Covered panel (small)

6-11Covered panel (medium)

>11Not covered

>7d

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

87505/6/7Referenced CPTs

Coverage Criteria for Multiplex GI PCR Panels

Multiplex PCR (up to 5 targets) coverage

Covered when ANY one of the following clinical circumstances is present and testing is performed as part of an evaluation that includes blood cultures:

Clinical indications: Diarrhea for more than 7 days; OR Diarrhea with at least one of fever, bloody or mucoid stools, severe abdominal cramping or tenderness, signs of sepsis; OR Suspected enteric fever in a person with recent travel to an endemic region or who consumed food prepared by someone with recent endemic exposureN/A

Testing limited to panels including up to 5 targets when paired with blood cultures.

Multiplex PCR (6-11 targets) coverage

Covered for evaluation of persistent diarrhea in individuals with any one of the following:

Persistent diarrhea group: At risk for Clostridium difficile colitis with either diarrhea >7 days OR diarrhea with fever, bloody or mucoid stools, severe abdominal cramping or tenderness, or signs of sepsis; OR AIDS; OR On immunosuppressive medications (post-transplant or for autoimmune disease); OR Other immunosuppressive condition when other stool diagnostic studies have failed to yield a pathogenic organismN/A

Applies to panels including up to 11 targets.

Preferred clinical scenarios for multiplex GI panel use

Evidence and guideline–informed indications where testing is most likely to be useful

IDSA-aligned clinical criteria: Ordering aligned with IDSA 2017 (eg, fever, abdominal pain, bloody stool, immunocompromised status) increases clinical yield and is a prioritized indication for multiplex panel testing

Clark et al. (2019) found applying IDSA criteria could reduce testing by ~32% without loss of sensitivity.

Severe or inpatient cases: Hospitalized patients or those with severe presentations where rapid identification could change management (influence isolation, antibiotic stewardship); panels may shorten time to result and reduce unnecessary antibiotics

Keske et al. (2018) and other observational studies reported reduced unnecessary antibiotic use and faster reporting times.

Situations needing rapid detection for infection control or targeted therapy: Outbreaks, infection control decisions, or traveler’s diarrhea where broader detection alters early management

Systematic reviews and cohort data (Meyer et al., Pouletty) indicate increased pathogen detection that can enable earlier targeted treatment, though carriage rates must be considered.

Non-sufficient-alone scenarios / confirmatory testing

Limitations and scenarios where multiplex panels are insufficient alone

When culture is needed: When antimicrobial susceptibility, subtyping for public health, or detection of organisms not included in the panel is required, routine culture should be performed in parallel or instead

Studies and systematic reviews note that panels cannot replace culture for susceptibility testing or detection of organisms not on the panel; culturing from positive samples may be required.

High positivity but uncertain clinical significance: High detection rates and carriage in asymptomatic individuals mean positive results may not indicate causation; results require clinical correlation

Meyer et al. and Freeman et al. highlighted increased positives and uncertain clinical importance of additional findings.

Targets with discordant performance: Some bacterial targets (eg, Salmonella) demonstrate discordant sensitivity/specificity compared with culture; confirmatory or parallel testing is recommended

Prospective and analytic studies reported suboptimal PPA for some shared bacterial targets and recommended enrichment culture for Salmonella.

Medically Necessary Indications

Covered when ANY of the following guideline-supported clinical criteria are met

Indications: Patient with moderate to severe diarrhea, bloody diarrhea, febrile diarrhea, dysenteric features, nosocomial onset (>3 days for non-C. difficile pathogens), persistent diarrhea, or immunocompromised host; testing supports pathogen-directed therapy or infection control actions

Based on IDSA and ACG guideline recommendations.

Situations Where Testing Is Not Typically Indicated

Not routinely covered / Not recommended when ALL of the following are present

Not indicated for: Uncomplicated, self-limited acute gastroenteritis of short duration without systemic features; cases where testing is unlikely to change management (eg, typical viral gastroenteritis in immunocompetent patients and short-duration noninflammatory diarrhea)

IDSA guidance generally does not recommend testing for noninflammatory, limited-duration diarrhea.

Interpretation and Special Pathogen Notes

Additional considerations

Test interpretation: Positive NAAT results must be interpreted in clinical context because detection may represent colonization or nonviable organisms; two-step algorithms are preferred for C. difficile to distinguish colonization from infection

ACG recommends combining a highly sensitive and a highly specific test for C. difficile; NAATs should not be regarded as tests of cure.

Multiplex PCR panel testing for gastrointestinal pathogens performed for indications other than those specified in this policy and panels with >11 targets are considered unproven and not medically necessary. This aligns with the policy statement that such broader panel use lacks sufficient evidence of efficacy and therefore is excluded from coverage.

Routine, unrestricted use of broad multiplex panels in low‑risk outpatient adults where established guideline (eg, IDSA) criteria are not met is discouraged. Systematic reviews and observational studies show higher overall detection rates with multiplex panels but uncertain clinical significance of additional positives; applying IDSA criteria can reduce unnecessary testing without materially reducing clinical yield.

Do not rely exclusively on multiplex PCR panels when organism isolation is necessary for antimicrobial susceptibility testing or public‑health subtyping. Multiplex panels do not provide isolates for susceptibility or subtyping; culture from positive specimens may be required to guide therapy or surveillance.

Multiplex PCR panel testing for clinical indications not listed as proven in this policy and panels with >11 targets are considered unproven and not medically necessary. The policy therefore does not cover broader panel usage outside the specified coverage criteria.

Testing asymptomatic individuals or ordering broad multiplex panels without documented, relevant clinical features (for example, no fever, no bloody stool, no severe symptoms, and not immunocompromised) is low yield and is not supported. Studies indicate additional positive findings from panels often lack clear clinical consequence, increasing the potential for unnecessary treatment.

Routine use of broad multiplex panels in patients with noninflammatory, self‑limited diarrhea is not routinely indicated. IDSA and guideline guidance recommend against laboratory testing for uncomplicated, short‑duration, noninflammatory gastroenteritis because results are unlikely to change management.

When Testing Is Covered

Evaluation of suspected infectious diarrhea meeting specified clinical criteria

Evaluation of suspected infectious diarrhea meeting specified clinical criteria (see criteria_sets), including persistent diarrhea or immunocompromised status.

Covered scenarios: Different panel sizes mapped to clinical scenarios: 3-5 target panels when testing is part of an evaluation that includes blood cultures; 6-11 target panels for evaluation of persistent diarrhea or immunocompromised cases

See detailed criteria for specific clinical features (eg, duration >7 days, fever, bloody stools, immunocompromised status).

Acute infectious diarrhea with clinically significant features

Acute infectious diarrhea with clinically significant features (eg, bloody diarrhea, systemic signs, severe disease, hospitalized patients, immunocompromised individuals, traveler's diarrhea)

Clinical features: Hospitalized patients or those with severe presentations where rapid identification could change management (eg, influence isolation or antibiotic decisions); testing may improve time to pathogen identification and influence stewardship actions

CPT Codes, Panel Sizes, and Examples

Documentation Required

Referenced CPT codes and panel-size mapping — Coverage guidance and provider actions

Provider actions and documentation requirements (billing_rule/documentation): Order panels that match guideline-based risk criteria (e.g., moderate-to-severe, bloody, febrile, dysenteric, nosocomial, persistent diarrhea, immunocompromised host, travel-associated enteric fever risk). Clearly document the clinical indication in the medical record, including duration of diarrhea, presence of fever, bloody/mucoid stools, severe abdominal pain/tenderness, signs of sepsis, immunocompromised status, recent travel to endemic regions, or failure of other stool studies. For panels >11 targets (CPT 87507), explicitly document why a larger panel is required and obtain prior authorization when applicable. Parallel conventional culture for Salmonella is suggested when bacterial pathogens are suspected to allow isolate recovery for antimicrobial susceptibility and public health reporting. Adjunct conventional testing (e.g., C. difficile testing, ova and parasite microscopy or antigen testing, stool culture where indicated) should be performed as clinically appropriate and documented.

Referenced CPT to panel mapping: 87505 (3-5 targets), 87506 (6-11 targets), 87507 (12-25 targets)
Guideline-based ordering risk: moderate-to-severe, bloody, febrile, dysenteric, nosocomial, persistent diarrhea, immunocompromised, travel-associated enteric fever
Indication documentation: duration of symptoms, specific signs (fever, bloody stools, sepsis), immunocompromised status, travel history

What Providers Should Do

Prior Authorization

Prior authorization may be required for non-targeted panel use

Prior authorization may be required when broad multiplex panels are ordered outside the policy’s restricted, guideline-aligned indications because evidence supports targeted use and limited clinical utility in low‑yield populations.

Evidence reviews recommend restricted ordering to individuals likely to benefit to avoid low‑yield testing (Meyer et al., Clark et al.).
Payer may require prior authorization for panels ordered outside the covered criteria or routinely in low‑yield outpatient populations.

Prior Authorization

Check plan-specific prior authorization and contractual rules

Verify federal, state, and contractual benefit plan requirements before ordering; plan-specific rules may impose prior authorization or different coverage decisions that take precedence over this policy.

In the event of conflict, federal, state, or contractual requirements govern coverage determinations.
Check benefit plan–specific prior authorization rules prior to ordering.

Ordering and Documentation Requirements

Note

No explicit ordering restriction — ensure documentation supports medical necessity

No explicit restriction on who may order the test is provided in this excerpt, but ordering should be supported by medical record documentation demonstrating that coverage criteria are met.

Policy states no explicit ordering restrictions in this portion and notes documentation may be required to demonstrate criteria are met.

Note

Order based on guideline-aligned clinical criteria and likelihood to change management

Guidance recommends ordering be guided by clinical criteria (for example, IDSA 2017) and documented signs/symptoms; panels are most useful when results will change patient management (isolation, antibiotic decisions, or infection control).

IDSA and evidence summaries support prioritizing testing in hospitalized or severe cases where results could affect management.

Services Not Covered

Panels with more than 11 targets (eg, 12–25 target assays) are specifically identified in this policy as not covered. These assays are described in product and CPT mapping as larger, highly multiplexed panels and are excluded from coverage due to insufficient evidence of clinical benefit.

Unrestricted use of multiplex panels in low‑risk outpatient populations without guideline‑based indications is not covered. Evidence reviews report increased detection but uncertain clinical impact and risk of false positives; therefore routine panel testing in low‑yield settings is excluded from coverage.

Use of multiplex panels as a substitute for culture when an isolate is needed for antimicrobial susceptibility testing or public‑health subtyping is not covered. The policy notes that culture or culture from positive samples may be required when susceptibility or subtyping is clinically necessary.

Definitions and Test Characteristics

inv-32: Multiplex PCR panel — A nucleic acid-based assay that detects multiple gastrointestinal pathogens simultaneously using PCR technology; panel size refers to the...

DefinitionA nucleic acid–based assay that detects multiple gastrointestinal pathogens simultaneously using PCR technology; panel size refers to the number of targets (e.g., 3–5, 6–11, 12–25).

FunctionProvides rapid, culture-independent detection of bacterial, viral, and parasitic nucleic acid from stool or rectal specimens.

LimitationsPanel composition is fixed to included organisms and may not detect all parasites; results may detect nonviable organisms and do not provide susceptibility.

inv-33: Syndromic multiplex panel — A molecular assay that simultaneously tests for multiple gastrointestinal pathogens (viruses, bacteria, parasites) from a single stool or rectal specimen.

DefinitionA molecular assay that simultaneously tests for multiple gastrointestinal pathogens (viruses, bacteria, parasites) from a single stool or rectal specimen.

Frequency and Repeat Testing

inv-40: No explicit frequency limits stated in this portion of the policy.

Frequency statementNo explicit frequency limits stated in this portion of the policy.

Documentation noteMedical records documentation may be required to demonstrate that coverage criteria are met; absence of frequency limits does not guarantee coverage.

Ordering implicationOrder according to clinical indications and plan-specific requirements; verify prior authorization rules if applicable.

inv-41: No explicit repeat frequency limits provided in this document portion.

Repeat testing frequencyNo explicit repeat frequency limits provided in this document portion.

Clinical judgmentRepeat testing should be guided by clinical change or new indications rather than routine schedules.

Background and Clinical Context

Acute infectious diarrhea has many causes, including bacterial, viral, and parasitic agents. Most self‑limited, noninflammatory diarrheas do not require diagnostic testing; stool testing (culture or culture‑independent methods) is recommended primarily for patients with moderate to severe, bloody, febrile, dysenteric, nosocomial, or persistent diarrhea, or for those who are immunocompromised. Although multiplex PCR assays can increase detection rates and shorten turnaround time, limitations include panel composition, inability to provide susceptibility data, and detection of nucleic acid from nonviable organisms—factors that affect clinical interpretation and utility.

Policy Revision History

2026-02-01Policy effective dateLatest

Policy CS169.Q became effective with updated Description of Services, Clinical Evidence, and References sections; removed prior Louisiana‑specific language and archived the previous policy version CS169.P.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyGastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea

Policy CodePolicy CS169.Q

Change TypeRevised clinical evidence and referencestemplate language removed

Effective DateFeb 1, 2026

Next Review Date

SourceLink

On This Page

Prospective studies (Keske et al.) and systematic reviews report higher detection rates and potential reductions in unnecessary antibiotic use.

Suspected gastrointestinal infection in solid organ transplant recipients

SOT considerations: Use multiplex molecular assays to identify Cryptosporidium, Cyclospora, and Giardia in solid organ transplant recipients with suspected GI infection

Recommendation per transplantation infectious disease community guidance.

Patients with moderate to severe, bloody, febrile, dysenteric, nosocomial, persistent, or immunocompromised-associated diarrhea

Priority patients: Testing is indicated for patients presenting with moderate to severe, bloody, febrile, dysenteric, nosocomial-onset, persistent, or immunocompromised-associated diarrhea to guide therapy and infection control

Supported by IDSA and ACG guideline recommendations.

Clinical rationale documentation: reason for panel size selection and how results will impact management

Parallel culture suggested for Salmonella to permit susceptibility testing and public health reporting

Adjunct conventional testing recommended: C. difficile testing, ova & parasite studies, targeted stool cultures as clinically indicated

Step Therapy

Step-therapy not specified

No step-therapy requirements are specified in this policy excerpt.

Documentation Required

Perform parallel enrichment culture for Salmonella when using PCR

For Salmonella detection, enrichment culture performed in parallel with PCR is recommended because PCR may be less sensitive than culture for Salmonella in some comparative studies.

Hapuarachchi et al. found enrichment culture substantially more sensitive than PCR for Salmonella and recommended parallel enrichment culture testing.

Note

Consider adjunct conventional (culture-dependent) testing

When available, perform conventional culture or culture-dependent testing adjunctively (for antimicrobial susceptibility, public health subtyping, or when culture is required) rather than relying exclusively on multiplex panels.

Policy notes that culture should be performed in parallel or instead when susceptibility or subtyping is needed.
ACG and other guidance recommend adjunctive use of culture-dependent methods for certain clinical needs.

Documentation Required

Provide medical record documentation for coverage review

Medical record documentation may be required to demonstrate that the member meets the policy’s clinical criteria for coverage; documentation used for reviews follows the payer’s Medical Records Documentation Used for Reviews guidance.

Documentation may be requested to assess whether clinical criteria are met and does not guarantee coverage.

Documentation Required

Document clinical indications and symptoms

Record the patient’s clinical indications and relevant symptoms (e.g., bloody diarrhea, fever, severe symptoms, travel history, immunocompromised status) to support use of multiplex GI panels given variable clinical utility evidence.

IDSA-aligned criteria (fever, abdominal pain, bloody stool, immunocompromised status) increase clinical yield and should be documented.
Travel history and severe/systemic features are included among covered indications.

Documentation Required

Record clinical rationale for ordering multiplex panel

Document the clinical presentation and the rationale for testing (for example: fever, bloody stools, duration >7 days, immunocompromised status, or nosocomial onset) to align with guideline recommendations and support coverage.

ACG and IDSA guidance indicate documentation of symptom severity and duration (>7 days for some parasite considerations) is relevant to testing decisions.

Denial Risk

Panels >11 targets or non‑specified indications may be denied as not medically necessary

Multiplex PCR panels for gastrointestinal pathogens for indications not listed as covered, and panels with >11 targets, are considered unproven and not medically necessary and may be denied.

Policy explicitly lists multiplex PCR testing for all other indications and panels >11 targets as not medically necessary.

Denial Risk

Risk of low‑yield testing if IDSA guideline criteria are not followed

Ordering tests outside guideline-based clinical criteria (for example, IDSA 2017 criteria: fever, abdominal pain, bloody stool, or immunocompromised state) reduces clinical yield and may lead to low‑yield testing.

Clark et al. demonstrated applying IDSA criteria could reduce testing by ~32% without reducing clinical yield.

Denial Risk

Indication-based denial risk for testing outside recommended clinical scenarios

Tests are generally indicated for patients with moderate to severe, bloody, febrile, dysenteric, nosocomial, or persistent diarrhea or who are immunocompromised; ordering tests outside these indications risks being unsupported by guideline recommendations and may be denied.

IDSA guidance recommends fecal testing for patients with moderate to severe, bloody, febrile, dysenteric, nosocomial, persistent diarrhea, or immunocompromised status.

Billing Rule

Confirm ordering meets plan‑specific contractual and state requirements

Order tests in accordance with plan‑specific contractual and state requirements and verify benefit plan–specific prior authorization and applicable federal/state contractual rules before ordering.

This Medical Policy is interpretive; federal, state, or contractual requirements govern if there is conflict.

Use casesUseful for hospitalized or immunocompromised patients and outbreak/infection-control scenarios where rapid broad detection informs management.

LimitationsPanel size, cost, and potential for detecting clinically insignificant organisms are noted limitations; interpret with clinical correlation.

inv-34: Multiplex gastrointestinal PCR/panel — A culture-independent NAAT that simultaneously tests a single stool specimen for multiple bacterial, viral, and parasitic pathogens; exam...

DefinitionA culture-independent NAAT that simultaneously tests a single stool specimen for multiple bacterial, viral, and parasitic pathogens; examples include FilmArray, xTAG, Verigene, and BioCode panels.

AdvantagesGreater sensitivity and faster turnaround time compared with culture; may detect pathogens requiring specialized culture techniques.

Practical limitationCannot replace culture when antimicrobial susceptibility testing or public health subtyping is required; culture from positive samples may be necessary.

inv-35: NAAT limitation — Nucleic acid amplification tests detect DNA/RNA and cannot reliably distinguish viable organisms (active infection) from colonization or ...

Key limitationNAATs detect DNA/RNA and cannot reliably distinguish viable organisms (active infection) from colonization or nonviable organisms; not recommended as 'test of cure.'

Clinical implicationPositive NAAT results require clinical correlation; two-step algorithms (eg, for C. difficile) are recommended to reduce false-positive interpretation.

Impact on public health/susceptibilityBecause NAATs do not produce isolates, culture may be required in parallel for susceptibility testing or public health subtyping.

Prior auth considerationPlan-specific prior authorization rules may still apply to repeat or non-targeted panel use.

inv-42: (redundant) No specific frequency limits stated

Frequency limits summaryNo specific frequency limits stated in this policy excerpt.

Clinical implicationTesting frequency decisions should follow clinical criteria (eg, IDSA/ACG) and local plan requirements.

DocumentationMaintain clinical documentation supporting the medical necessity of repeat or multiple tests.